LifeVantage Corporation reported second quarter fiscal 2026 earnings of $0.15 per diluted share, missing the Zacks Consensus Estimate of $0.22 and down from $0.22 per share in the year-ago quarter. Net income for the quarter was $0.3 million, compared with $2.6 million a year earlier. Adjusted non-GAAP earnings per diluted share declined to $0.15 from $0.22, reflecting inventory reserves and higher fulfillment costs associated with its MindBody GLP-1 System™ launch cycle.

Total revenue for the quarter ended December 31, 2025 was $48.9 million, a 27.8% decrease from the prior year period but a 2.9% sequential increase over Q1. In the Americas, revenue fell 32.6% year-over-year due to cycling MindBody GLP-1 System sales, partially offset by LoveBiome® product line contributions following its October 2025 acquisition. Asia/Pacific & Europe revenue declined 2.1% (3.7% on a constant currency basis). Gross profit margin contracted to 74.0% from 80.5% a year ago, principally driven by a $2.4 million inventory obsolescence allowance, while adjusted non-GAAP gross margin was 78.8%. Commissions and incentives expenses represented 40.7% of revenue, down from 48.0%, and SG&A increased to 32.3% of revenue from 27.5%. Adjusted EBITDA fell to $3.9 million, compared with $6.5 million in the prior-year quarter.

LifeVantage ended December 31, 2025 with $10.2 million in cash and cash equivalents and no outstanding debt, down from $20.2 million at June 30, 2025. Operating cash flow for the first six months of fiscal 2026 was $0.5 million versus $8.6 million a year earlier. The company repurchased 44,000 shares for $0.6 million during the period and announced a new $60 million share repurchase authorization through December 31, 2027. A quarterly cash dividend of $0.045 per share will be paid on March 16, 2026. For fiscal 2026, management forecasts revenue of $185 million to $200 million, adjusted EBITDA of $15 million to $19 million, and adjusted EPS of $0.60 to $0.80, assuming an annual tax rate near 23%.

Steve Fife, who has served as President and Chief Executive Officer for nine years, will retire in April 2026. During the transition period he will remain in his roles to ensure continuity. The Board of Directors is conducting an extensive search for his successor and expects to announce the new CEO in the coming months. Raymond Greer, Board Chairman, praised Fife’s strategic leadership in expanding the company’s product portfolio and global footprint.